Janssen to Unveil New Hepatitis B and C Data at The International Liver Congress(TM) 2016 of the European Association fo

-  LBO6: NVR 3-778, a first-in-class HBV core inhibitor, alone and in combination

with peginterferon (PEGIFN), in treatment-naive HBeAG-positive patients: Early

reductions in HBV DNA and HBeAG 

Oral presentation is under embargo until Saturday 16 April, 07:00 CET

Lead Author: Man-Fung Yuen**

* Alios BioPharma, Inc. and Novira Therapeutics Inc. Both part of the Janssen Pharmaceutical Companies 

**Full session details and data presentation listings for The International Liver Congress(TM) 2016 can be found at http://www.ilc-congress.eu.

Janssen in Viral Hepatitis  

At Janssen, our commitment is to make hepatitis history by contributing to the elimination of viral hepatitis as global public health concern. Leveraging our vast research and development experience in viral diseases, we have co-developed two approved treatments for chronic hepatitis C (telaprevir, simeprevir) and are striving to bring forth further transformational medical innovations for chronic hepatitis B and C to improve the lives of all those affected by viral hepatitis.

We are developing a new combination regimen in hepatitis C which has the potential to treat and cure a broad range of people living with this disease. And seek to overcome the treatment challenges in hepatitis B, such as the requirement for people to require lifelong therapy, with the aim of developing a functional cure.  

With goals like this, there's no time to waste. That is why we partner with organizations around the world, connecting our own expertise with that of others. Because, only together we can Make Hepatitis History.

About Hepatitis  

Hepatitis C, a blood-borne infectious disease of the liver and a leading cause of chronic liver disease, is the focus of a rapidly evolving treatment landscape. Approximately 150 million people are infected with hepatitis C worldwide and 350,000 people per year die from the disease globally. When left untreated, hepatitis C can cause significant damage to the liver including cirrhosis. Additionally, hepatitis C may increase the risk of developing complications from cirrhosis, which may include liver failure. Similarly, chronic hepatitis B (HBV) causes approximately 650,000 deaths worldwide from cirrhosis and liver cancer, with approximately 60 percent of hepatocellular carcinoma attributed to hepatitis B infection. Current recommended therapies are unable to cure the infection, requiring most people to continue treatment for life.

About Janssen Pharmaceutical Companies of Johnson & Johnson 

At Janssen, we are dedicated to addressing some of the most important unmet medical needs in oncology, immunology, neuroscience, infectious diseases and vaccines, and cardiovascular and metabolic diseases. Driven by our commitment to patients, we develop innovative products, services and healthcare solutions to help people throughout the world. For more information, visit http://www.janssen.com or follow @JanssenGlobal.

Cautions Concerning Forward-Looking Statements 

This press release contains "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995 regarding product development. The reader is cautioned not to rely on these forward-looking statements. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or known or unknown risks or uncertainties materialize, actual results could vary materially from the expectations and projections of Janssen Sciences Ireland UC, any of the other Janssen Pharmaceutical Companies and/or Johnson & Johnson. Risks and uncertainties include, but are not limited to: challenges inherent in product research and development, including uncertainty of clinical success and obtaining regulatory approvals; uncertainty of commercial success; competition, including technological advances, new products and patents attained by competitors; challenges to patents; changes to applicable laws and regulations, including global health care reforms; and trends toward health care cost containment. A further list and description of these risks, uncertainties and other factors can be found in Johnson & Johnson's Annual Report on Form 10-K for the fiscal year ended January 3, 2016, including in Exhibit 99 thereto, and the company's subsequent filings with the Securities and Exchange Commission. Copies of these filings are available online at http://www.sec.gov, http://www.jnj.com or on request from Johnson & Johnson. None of the Janssen Pharmaceutical Companies or Johnson & Johnson undertakes to update any forward-looking statement as a result of new information or future events or developments.

Photo:

http://photos.prnewswire.com/prnh/201403...

CONTACT: Media Contact: Ronan Collins, +47-(0)488-425-00,rcollin5@its.jnj.com. Investor Relations: Lesley Fishman, Phone:+1-732-524-3922.